Table 1.

Clinical characteristics of 857 allo-HSCT patients transplanted at MSKCC

Dates of transplant	May 1992 to July 2015
Age (years)	18 to 77, median 49
Gender	Female 341 (40%), male 516 (60%)
Primary malignancy	NHL 242 (28%), AML 277 (32%), CML 48 (5.6%), MDS/MPD 71 (8.3%), ALL 74 (8.6%), CLL 41 (4.8%), Hodgkin disease 70 (8.2%), multiple myeloma 24 (2.8%), other hematological malignancies 16 (1.9%), other malignancies 8 (0.9%), non-malignant hematological disorders 22 (2.6%)
Graft source	Peripheral blood 497 (58%), cord blood 197 (23%), bone marrow 163 (19%)
Conditioning intensity	Standard intensity myeloablative 305 (36%), reduced intensity myeloablative 283 (33%), nonmyeloablative 268 (31%)
HLA matching	HLA identical 604 (70%), HLA mismatch 253 (30%)
Antibiotics for neutropenic fever	No antibiotics for neutropenic fever 474 (55%)
	Imipenem-cilastatin or piperacillin-tazobactam first-line 306 (36%)
	Received imipenem-cilastatin only 6 (0.7%)
	Received piperacillin-tazobactam only 183 (21%)
	Received both 117 (14%)
	Also received aztreonam or cefepime 106 (12%)
	Aztreonam or cefepime first-line 77 (9%)
	Received aztreonam only 18 (2.1%)
	Received cefepime only 40 (4.7%)
	Received both 19 (2.2%)
	Also received imipenem-cilastatin 23 (2.7%)